Results 261 to 270 of about 30,003 (287)

Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA). [PDF]

Drugs R D
Thaçi D, Gerdes S, Schulze-Koops H, Allanore Y, Kavanaugh A, Both C, Gattu S, Hachaichi S, Matucci-Cerinic M.   +8 more
europepmc   +1 more source

Successful Treatment of Refractory Mucocutaneous Behçet's Disease With Gastrointestinal Involvement Using Anti-tumor Necrosis Factor-Alpha (Anti-TNF-α) Therapy. [PDF]

Cureus
Elfatih Mohamed M, Mazin Al-Issa R, Ahmed H, Emad Al-Zaidy A, Elbadawi F.   +4 more
europepmc   +1 more source

Comparing Long-Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern. [PDF]

J Gastroenterol Hepatol
Suo P, Srinivasan A, Thin L, An YK, Fernandes RG, Ghaly S, Jeffrey AW, Menon S, Olsen N, Skinner T, van Langenberg DR, Winston J, Haifer C.   +12 more
europepmc   +1 more source

Facilitators and barriers to generic and biosimilar medications in the Middle East and North Africa: insights from physicians and pharmacists-a systematic review. [PDF]

Eur J Clin Pharmacol
Alqawasmeh KA, Mason T, Morris A, Hafez W, Hasan T, Taher S, Al Dweik R.   +6 more
europepmc   +1 more source

RETRACTION: Evaluation of Bevacizumab Biosimilar on Wound Healing Complications in Patients with Colorectal Cancer Undergoing Endoscopic Mucosal Resection: A Systematic Review and Meta-Analysis in Anorectal Medicine. [PDF]

Int Wound J
europepmc   +1 more source

Global Harmonization of Biosimilar Development by Overcoming Existing Differences in Regional Regulatory Requirements - Outcomes of a Descriptive Review. [PDF]

Ther Innov Regul Sci
Kirchlechner TM, Cohen HP.
europepmc   +1 more source

Regulierung und adäquate Preisbildung im Markt der Biosimilars: Projekt im Auftrag der Pfizer Deutschland GmbH

, 2017
Altin, Sibel, Bauer, Cosima, May, Uwe, Walendzik, Anke, Wasem, Jürgen, Ziebe, Anissa   +5 more
core  

Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12.

J Clin Endocrinol Metab
Langdahl B, Chung YS, Plebanski R, Czerwinski E, Dokoupilova E, Supronik J, Rosa J, Mydlak A, Rowińska-Osuch A, Baek KH, Urboniene A, Mordaka R, Ahn S, Rho YH, Ban J, Eastell R.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biosimilars

Lupus, 2020
Biological therapies have widened the therapeutic armamentarium for immune-mediated inflammatory diseases, providing in many cases a broad range of treatment options with different mechanisms of action. The widespread use of biological agents in systemic lupus erythematosus is currently limited to belimumab and rituximab, although results of promising
Christopher J Edwards, Salvatore Bellinvia   +1 more
openaire   +2 more sources